Acumen nominates ACU301, ACU401 Enhanced Brain Delivery Alzheimer’s candidates, targets mid-2027 IND filing

Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc.

ABOS

0.00
  • Acumen nominated two Enhanced Brain Delivery Alzheimer’s candidates, ACU301 and ACU401, advancing its bispecific antibody program with JCR’s brain-penetration platform.
  • Preclinical studies disclosed earlier supported the move, showing stronger brain exposure and a clean safety profile versus conventional antibody formats.
  • Additional data will be presented at a future medical meeting.
  • IND-enabling work is ongoing, targeting an IND submission in mid-2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief on June 16, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.